Goodwin Advises Hansoh on Collaboration Agreement With Roche for $400 Million Upfront and Up To $15 Billion in Milestone Payments

The Life Sciences and Technology teams advised Hansoh Pharma (“Hansoh”) on entering into a strategic collaboration and license agreement with Roche.

Hansoh will receive an upfront payment of $400 million as well as a first anniversary payment of $110 million and be eligible to receive potentially more than $15 billion in milestone payments associated with the development, regulatory approval, and commercialization of the programs, as well as tiered royalties on potential future product sales. Under the collaboration agreement, Hansoh will lead the early development of the programs up to the completion of global Phase 1a clinical trials. Roche will be responsible for further developing the programs worldwide, excluding the Chinese Mainland, Hong Kong, Macau, and Taiwan, where Hansoh will retain all rights to develop, register, and commercialize the programs.

Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise in China. With the mission of “continuous innovation for better life,” the company focuses on major disease therapeutic areas such as oncology, metabolism, immunology, central nervous system (CNS), and anti-infectives. Hansoh Pharma has launched seven innovative medicines that generate product sales in China, with the revenue from innovative medicines and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies, is recognized as one of the top three pharmaceutical R&D enterprises in China, and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise.

The Goodwin team was led by Wenseng “Wendy” Pan and included Christopher Zhong, Longfei Fang, Paul Jin, Ortal Ben Aharon, Arom Yun, Bill Christiansen, and Xixi Sun.

For more information on the deal, please read the press release.